Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials.

Erpeldinger S, Rehman MB, Berkhout C, Pigache C, Zerbib Y, Regnault F, Guérin E, Supper I, Cornu C, Kassaï B, Gueyffier F, Boussageon R.

BMC Endocr Disord. 2016 Jul 8;16(1):39. doi: 10.1186/s12902-016-0120-z.

2.

Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus.

Inagaki N, Harashima S, Maruyama N, Kawaguchi Y, Goda M, Iijima H.

Cardiovasc Diabetol. 2016 Jun 18;15(1):89. doi: 10.1186/s12933-016-0407-4.

3.

Safety, efficacy, and early clinical experience of insulin degludec in Japanese people with diabetes mellitus: A first-year report from Japan.

Kaku K, Eid MA.

J Diabetes Investig. 2015 Nov;6(6):610-9. doi: 10.1111/jdi.12348. Epub 2015 Apr 20. Review.

4.

Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement.

Kalra S, Aamir AH, Raza A, Das AK, Azad Khan AK, Shrestha D, Qureshi MF, Md Fariduddin, Pathan MF, Jawad F, Bhattarai J, Tandon N, Somasundaram N, Katulanda P, Sahay R, Dhungel S, Bajaj S, Chowdhury S, Ghosh S, Madhu SV, Ahmed T, Bulughapitiya U.

Indian J Endocrinol Metab. 2015 Sep-Oct;19(5):577-96. doi: 10.4103/2230-8210.163171. Review.

5.

Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study.

Seong JM, Choi NK, Shin JY, Chang Y, Kim YJ, Lee J, Kim JY, Park BJ.

PLoS One. 2015 May 20;10(5):e0124287. doi: 10.1371/journal.pone.0124287. eCollection 2015.

6.

Breaking down barriers to initiating insulin: Insulin prescription pad.

Ali A, Cheng AY, Yu CH.

Can Fam Physician. 2015 May;61(5):445-7. No abstract available.

7.

Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications.

Alvarez CA, Lingvay I, Vuylsteke V, Koffarnus RL, McGuire DK.

Clin Pharmacol Ther. 2015 Aug;98(2):145-61. doi: 10.1002/cpt.143. Epub 2015 Jul 3. Review.

PMID:
25963811
8.

A combined analysis of 48 type 2 diabetes genetic risk variants shows no discriminative value to predict time to first prescription of a glucose lowering drug in Danish patients with screen detected type 2 diabetes.

Hornbak M, Allin KH, Jensen ML, Lau CJ, Witte D, Jørgensen ME, Sandbæk A, Lauritzen T, Andersson Å, Pedersen O, Hansen T.

PLoS One. 2014 Aug 26;9(8):e104837. doi: 10.1371/journal.pone.0104837. eCollection 2014.

9.

Optimal management of type 2 diabetes in patients with increased risk of hypoglycemia.

Anderson M, Powell J, Campbell KM, Taylor JR.

Diabetes Metab Syndr Obes. 2014 Mar 6;7:85-94. doi: 10.2147/DMSO.S48896. eCollection 2014. Review.

10.

Assessment of pancreatic β-cell function: review of methods and clinical applications.

Cersosimo E, Solis-Herrera C, Trautmann ME, Malloy J, Triplitt CL.

Curr Diabetes Rev. 2014 Jan;10(1):2-42. Review.

11.

Age-specific effectiveness and safety of newly initiated insulin therapy in Japanese patients with uncontrolled diabetes.

Shiga T, Yokokawa H, Taneda Y, Sugihara E, Meijyo M, Mitsuhashi K, Hisaoka T, Isonuma H.

Diabetes Ther. 2013 Dec;4(2):473-86. doi: 10.1007/s13300-013-0049-4. Epub 2013 Dec 10.

12.

Personalizing guidelines for diabetes management: twilight or dawn of the expert?

Paschou SA, Leslie RD.

BMC Med. 2013 Jul 10;11:161. doi: 10.1186/1741-7015-11-161. Review.

13.

The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes.

Tschöpe D, Hanefeld M, Meier JJ, Gitt AK, Halle M, Bramlage P, Schumm-Draeger PM.

Cardiovasc Diabetol. 2013 Apr 10;12:62. doi: 10.1186/1475-2840-12-62. Review.

14.

Insulin detemir attenuates food intake, body weight gain and fat mass gain in diet-induced obese Sprague-Dawley rats.

Rojas JM, Printz RL, Niswender KD.

Nutr Diabetes. 2011 Jul 4;1:e10. doi: 10.1038/nutd.2011.6.

15.

Future detection and monitoring of diabetes may entail analysis of both β-cell function and volume: how markers of β-cell loss may assist.

Neutzsky-Wulff AV, Andreassen KV, Hjuler ST, Feigh M, Bay-Jensen AC, Zheng Q, Henriksen K, Karsdal MA.

J Transl Med. 2012 Oct 30;10:214. doi: 10.1186/1479-5876-10-214.

16.

Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes.

Rosenstock J, Shenouda SK, Bergenstal RM, Buse JB, Glass LC, Heilmann CR, Kwan AY, MacConell LA, Hoogwerf BJ.

Diabetes Care. 2012 May;35(5):955-8. doi: 10.2337/dc11-1434. Epub 2012 Mar 19.

17.

Does hypoglycemia cause cardiovascular events?

Chopra S, Kewal A.

Indian J Endocrinol Metab. 2012 Jan;16(1):102-4. doi: 10.4103/2230-8210.91203.

18.

Incretin therapy--present and future.

Garber AJ.

Rev Diabet Stud. 2011 Fall;8(3):307-22. doi: 10.1900/RDS.2011.8.307. Epub 2011 Nov 10. Review.

19.

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations.

Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Block L, Nicholson WK, Hutfless S, Bass EB, Bolen S.

Ann Intern Med. 2011 May 3;154(9):602-13. doi: 10.7326/0003-4819-154-9-201105030-00336. Epub 2011 Mar 14. Review. Erratum in: Ann Intern Med. 2011 Jul 5;155(1):67-8.

20.

Long-term effect of metformin on blood glucose control in non-obese patients with type 2 diabetes mellitus.

Ito H, Ishida H, Takeuchi Y, Antoku S, Abe M, Mifune M, Togane M.

Nutr Metab (Lond). 2010 Nov 12;7:83. doi: 10.1186/1743-7075-7-83.

Items per page

Supplemental Content

Write to the Help Desk